Cancer News and Research

Latest Cancer News and Research

Second-quarter 2009 operating highlights announced by Helicos Biosciences

Helicos BioSciences Corporation (NASDAQ: HLCS) announced today its operating highlights for the quarter ended June 30, 2009 and other recent developments following the filing of its Quarterly Report on Form 10-Q for the period ended June 30, 2009.

3 Sep 2009

Biosante and Cell Genesys to merge after stockholders' approval

BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and Cell Genesys, Inc. (NASDAQ: CEGE), today announced that each will hold a special stockholders meeting on September 30, 2009 at which time stockholders will be asked to approve the previously announced merger between the companies. On June 29, 2009, BioSante and Cell Genesys entered into a definitive merger agreement by which the companies will merge in an all-stock transaction, with BioSante as the surviving company.

3 Sep 2009

Biosante Pharmaceuticals and Cell Genesys to hold stockholders meeting for merger approval

BioSante Pharmaceuticals, Inc. and Cell Genesys, Inc. (NASDAQ:CEGE), today announced that each will hold a special stockholders meeting on September 30, 2009 at which time stockholders will be asked to approve the previously announced merger between the companies.

3 Sep 2009

Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine

Curis, Inc. (NASDAQ: CRIS), a drug development company focused on developing proprietary targeted medicines for cancer treatment, today announced that two publications describing clinical data generated with GDC-0449 were published in the current edition of The New England Journal of Medicine (NEJM).

3 Sep 2009

Biodelivery Sciences International to participate in investor conferences

BioDelivery Sciences International, Inc. today announced its participation in the upcoming investor conferences.

3 Sep 2009

Corporate restructuring announced by Akela Pharma to achieve several operational objectives

Akela Pharma, Inc., (TSX: AKL) and its wholly owned manufacturing subsidiary, PharmaForm, today announced a comprehensive corporate restructuring designed to achieve several operational objectives.

3 Sep 2009

First-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced financial results for the first quarter of fiscal year (FY) 2010 ended July 31, 2009. Total revenues for the first quarter of FY 2010 increased 345% to $6,750,000, compared to $1,517,000 for the comparable prior year quarter. This increase was primarily generated from increased government contract revenue and from increased sales by Avid Bioservices, the company's wholly owned contract manufacturing subsidiary.

3 Sep 2009

Medtronic's COPE-HCV clinical study commences

Medtronic, Inc., today reported the initiation and first enrollments of patients in COPE-HCV (COntinuous Interferon Delivery via the Medtronic Paradigm Pump Infusion System Clinical Evaluation for Chronic HCV), the company’s first-ever clinical study using an external pump infusion system to treat patients with the hepatitis C virus (HCV).

3 Sep 2009

SuperGen to present at two upcoming investment conferences

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, today announced that James S.J. Manuso, Ph.D., President and Chief Executive Officer, will present at two upcoming investment conferences.

3 Sep 2009

Delcath Systems begins operations facility in Queensbury, New York

Delcath Systems, Inc. (Nasdaq: DCTH), a Manhattan headquartered medical technology company testing its proprietary treatment method for primary and metastatic cancers to the liver, announced that it has signed a three-year lease with the option to buy on a 10,000 square foot facility in Queensbury, New York in which it plans to locate manufacturing of its Percutaneous Hepatic Perfusion (PHP(TM)) System.

3 Sep 2009

Elekta Holdings appoints new CEO

James Hoey has been named CEO of Elekta Holdings with overall responsibility for all of Elekta’s North American legal entities. He will also assume responsibility for Region North America, replacing Joseph Jachinowski who has decided to leave the company for an external position.

From Elekta 3 Sep 2009

Study assesses protective capabilities of DNA vaccines against SIV

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that data generated from a pre-clinical collaborative study by National Cancer Institute (NCI) and Inovio scientists were published in the scientific journal Proceedings of the National Academy of Sciences in a paper entitled: “DNA vaccination in rhesus macaques induces potent immune responses and decreases acute and chronic viremia after SIVmac251 challenge.”

3 Sep 2009

Green to Grow calls for support of the California Toxics-Free Babies and Toddlers Act

Green to Grow (www.greentogrow.com), a leading Los Angeles-based manufacturer of BPA-free baby bottles that provide a safe alternative to polycarbonate products containing Bisphenol A (BPA) - a chemical currently banned in Canada, Minnesota, Connecticut and under scrutiny in several European nations - is urging the public and California Assembly members to support the Toxics-Free Babies and Toddlers Act (SB 797).

3 Sep 2009

Fashion show to help raise public awareness of psoriasis

Today, Tim Gunn, television host and fashion consultant ("Project Runway," "Tim Gunn's Guide to Style") and chief creative officer of Liz Claiborne, Inc., is hosting the Addressing Psoriasis(TM) Fashion Show, sponsored by Amgen and Wyeth, in New York City.

3 Sep 2009

Study reports a potential new investigational therapy for skin cancer

A study published today in the New England Journal of Medicine reports a potential new investigational therapy for advanced and metastatic basal cell skin cancer tested at the Virginia G. Piper Cancer Center at Scottsdale Healthcare and other sites appears to demonstrate tumor shrinkage and limited side effects in patients.

3 Sep 2009

Two 2008 drug approval reports highlight Ceplene benefits

EpiCept Corporation today announced that Ceplene (histamine dihydrochloride) has been highlighted in two separate reports issued recently reviewing 2008 drug approvals in the European Union.

3 Sep 2009

IsoFlow Infusion catheter allows physicians to increase drug concentrations at targeted sites

Vascular Designs, a medical device company, today announced that its IsoFlow(TM) infusion catheter has secured 510(k) marketing clearance by the U.S. Food and Drug Administration (FDA) for the direct delivery of medications into highly targeted areas. An important application of IsoFlow may be in the treatment of cancer.

3 Sep 2009

ODAC calls for randomized study of Vion's Onrigin injection for treatment of the elderly AML patients

VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced the results of the Oncologic Drugs Advisory Committee (ODAC) Meeting at which data for its lead oncology therapeutic Onrigin(TM)(laromustine) Injection were presented for the indication of remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML).

3 Sep 2009

Nucletron announces financial results for the first half year of 2009

Nucletron, a global leader in radiation oncology, today announced strong financial results over the first half year of 2009. Despite challenging global economic conditions, Nucletron surpassed projections for the first half year.

3 Sep 2009

New probe for identifying chemical process affected proteins functions like GPS

Scientists in Michigan are reporting the development of a powerful new probe for identifying proteins affected by a key chemical process important in aging and disease. The probe works like a GPS or navigation system for finding these proteins in cells. It could lead to new insights into disease processes and identify new targets for disease treatments, the researchers say. Their study is scheduled for the Sept. 18 issue of ACS Chemical Biology, a monthly journal.

3 Sep 2009

Cancer News and Research

Latest Cancer News and Research

Second-quarter 2009 operating highlights announced by Helicos Biosciences

Biosante and Cell Genesys to merge after stockholders' approval

Biosante Pharmaceuticals and Cell Genesys to hold stockholders meeting for merger approval

Phase I clinical trial data of GDC-0449 published in the New England Journal Of Medicine

Biodelivery Sciences International to participate in investor conferences

Corporate restructuring announced by Akela Pharma to achieve several operational objectives

First-quarter fiscal 2010 results announced by Peregrine Pharmaceuticals

Medtronic's COPE-HCV clinical study commences

SuperGen to present at two upcoming investment conferences

Delcath Systems begins operations facility in Queensbury, New York

Elekta Holdings appoints new CEO

Study assesses protective capabilities of DNA vaccines against SIV

Green to Grow calls for support of the California Toxics-Free Babies and Toddlers Act

Fashion show to help raise public awareness of psoriasis

Study reports a potential new investigational therapy for skin cancer

Two 2008 drug approval reports highlight Ceplene benefits

IsoFlow Infusion catheter allows physicians to increase drug concentrations at targeted sites

ODAC calls for randomized study of Vion's Onrigin injection for treatment of the elderly AML patients

Nucletron announces financial results for the first half year of 2009

New probe for identifying chemical process affected proteins functions like GPS

Cancer Research - Second Edition eBook

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Newsletters you may be interested in